Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Journal article published in 2017 by
H. M. Earl,
L. Hiller 
,
J. A. Dunn,
C. Blenkinsop,
L. Grybowicz,
A.-L. Vallier,
I. Gounaris,
J. E. Abraham ,
L. Hughes-Davies,
K. McAdam,
S. Chan,
R. Ahmad,
T. Hickish,
D. Rea,
C. Caldas
and other authors.
,
J. A. Dunn,
C. Blenkinsop,
L. Grybowicz,
A.-L. Vallier,
I. Gounaris,
J. E. Abraham ,
L. Hughes-Davies,
K. McAdam,
S. Chan,
R. Ahmad,
T. Hickish,
D. Rea,
C. Caldas
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 